New hope for refractory lymphoma: tailored drug cocktail targets resistant cancer
NCT ID NCT07493330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Doctors will use genetic testing of the tumor to choose a personalized combination of drugs, including an experimental drug called zeprumetostat. The goal is to see if this tailored treatment can shrink or control the cancer. About 86 adults will take part in this early-phase study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug spare healthy cells while killing lymphoma?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Can a drug duo outsmart resistant lymphomas?
- Custom-Made vaccine aims to boost immune attack on kidney tumors
- New study aims to decode PTCL by genetic subtype